Ironwood Pharmaceuticals (NASDAQ:IRWD) Reaches New 52-Week Low at $5.47

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) hit a new 52-week low on Thursday . The company traded as low as $5.47 and last traded at $5.49, with a volume of 123669 shares. The stock had previously closed at $5.70.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on IRWD. Craig Hallum dropped their price target on Ironwood Pharmaceuticals from $18.00 to $14.00 and set a “buy” rating on the stock in a research note on Friday, May 10th. Wells Fargo & Company dropped their target price on Ironwood Pharmaceuticals from $20.00 to $14.00 and set an “overweight” rating on the stock in a research report on Friday, March 1st. Finally, StockNews.com upgraded Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $18.40.

Ironwood Pharmaceuticals Stock Up 9.1 %

The stock has a market cap of $953.26 million, a PE ratio of -0.90 and a beta of 0.51. The stock has a 50-day moving average of $6.90 and a 200 day moving average of $9.87.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.20). Ironwood Pharmaceuticals had a negative net margin of 254.41% and a negative return on equity of 28.45%. The company had revenue of $74.90 million during the quarter, compared to analyst estimates of $105.75 million. During the same period in the previous year, the firm posted $0.25 earnings per share. The company’s revenue was down 28.0% compared to the same quarter last year. On average, equities analysts anticipate that Ironwood Pharmaceuticals, Inc. will post 0.56 EPS for the current year.

Insider Buying and Selling at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, Director Catherine Moukheibir sold 44,426 shares of the business’s stock in a transaction that occurred on Thursday, June 6th. The stock was sold at an average price of $6.36, for a total value of $282,549.36. Following the completion of the transaction, the director now directly owns 84,207 shares of the company’s stock, valued at $535,556.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Julie Mchugh sold 22,766 shares of the company’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $6.29, for a total transaction of $143,198.14. Following the completion of the transaction, the director now directly owns 139,528 shares of the company’s stock, valued at approximately $877,631.12. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Catherine Moukheibir sold 44,426 shares of the company’s stock in a transaction that occurred on Thursday, June 6th. The stock was sold at an average price of $6.36, for a total value of $282,549.36. Following the transaction, the director now directly owns 84,207 shares of the company’s stock, valued at $535,556.52. The disclosure for this sale can be found here. 12.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. First Eagle Investment Management LLC raised its stake in shares of Ironwood Pharmaceuticals by 11.1% during the 4th quarter. First Eagle Investment Management LLC now owns 907,225 shares of the biotechnology company’s stock worth $10,379,000 after buying an additional 90,636 shares during the period. Eventide Asset Management LLC acquired a new position in shares of Ironwood Pharmaceuticals during the 4th quarter worth approximately $8,472,000. Walleye Capital LLC acquired a new position in Ironwood Pharmaceuticals in the 3rd quarter valued at $1,608,000. Norges Bank acquired a new position in Ironwood Pharmaceuticals in the 4th quarter valued at $9,321,000. Finally, 13D Management LLC raised its stake in Ironwood Pharmaceuticals by 971.8% in the 4th quarter. 13D Management LLC now owns 367,649 shares of the biotechnology company’s stock valued at $4,206,000 after purchasing an additional 333,348 shares during the last quarter.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.